IMR Press / CEOG / Volume 41 / Issue 6 / DOI: 10.12891/ceog17492014

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Proteomic investigation of the severe preeclampsia treatment by low molecular weight heparin
Show Less
1 The Department of Obstetrics and Gynecology, 2nd Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen
2 The Department of Obstetrics and Gynecology, Southern Medical University, Nanfang Hospital, Guangzhou
3 Department of Pathophysiology, Key Laboratory of Proteomics of Guangdong Province, Southern Medical University, Guangzhou (China)
Clin. Exp. Obstet. Gynecol. 2014, 41(6), 620–626; https://doi.org/10.12891/ceog17492014
Published: 10 December 2014
Abstract

Purpose: The primary goal of this study is to investigate the mechanism of severe preeclampsia (PE) treatment by low molecular weight heparin (LMWH). Materials and Methods: Using two-dimensional difference in-gel electrophoresis (2D-DIGE) combined with matrix assisted laser desorption ionization-time-of-flight/time-of-flight mass spectrometry (MALDI-TOF/TOF) approach to identify the proteins that expressed differently in the serum samples of five patients before and after subcutaneous injection of LMWH (0.4 ml/person). Results: Seven protein spots were identified in 2D-DIGE that show significant change in expression level after LMWH treatment. Further analysis of seven protein spots with MALDI-TOF/TOF identified six different proteins. To confirm the proteomic data, two meaningful proteins of the six proteins, alpha-1-acid glycoprotein (AGP) and serotransferrin are subjected to immunoblotting. All of the proteins are obviously down-regulated after LMWH treatment. Conclusions: PE is a pregnancy-specific disease that clinically manifests as new-onset hypertension and proteinuria after 20 weeks of gestation. LMWH is an effective treatment of severe PE. The present proteomics based investigation may provide a new angle to understand the mechanism of severe PE treatment with LMWH.
Keywords
Severe preeclampsia
LMWH
DIGE
MALDI-TOF/TOF
Human serum
Share
Back to top